Regulation of cell growth and death by Epstein-Barr virus.

[1]  G. Packham,et al.  Control of Cell Cycle Entry and Apoptosis in B Lymphocytes Infected by Epstein-Barr Virus , 1999, Journal of Virology.

[2]  T. Graf,et al.  Epstein-Barr Virus Encodes a Novel Homolog of the bcl-2 Oncogene That Inhibits Apoptosis and Associates with Bax and Bak , 1999, Journal of Virology.

[3]  R. Hay,et al.  Mutations in the IkBa gene in Hodgkin's disease suggest a tumour suppressor role for IκBα , 1999, Oncogene.

[4]  W. Hammerschmidt,et al.  LMP1 signal transduction differs substantially from TNF receptor 1 signaling in the molecular functions of TRADD and TRAF2 , 1999, The EMBO journal.

[5]  B. Sugden,et al.  The Linking Regions of EBNA1 Are Essential for Its Support of Replication and Transcription , 1999, Molecular and Cellular Biology.

[6]  B. Kempkes,et al.  The Proto-Oncogene c-myc Is a Direct Target Gene of Epstein-Barr Virus Nuclear Antigen 2 , 1999, Journal of Virology.

[7]  R. Ambinder,et al.  Expression of Epstein-Barr virus BamHI-A rightward transcripts in latently infected B cells from peripheral blood. , 1999, Blood.

[8]  M. Makuuchi,et al.  Detection of Epstein-Barr virus (EBV) in hepatocellular carcinoma tissue: a novel EBV latency characterized by the absence of EBV-encoded small RNA expression. , 1999, Virology.

[9]  J. Sample,et al.  Epstein-Barr Virus Regulates c-MYC, Apoptosis, and Tumorigenicity in Burkitt Lymphoma , 1999, Molecular and Cellular Biology.

[10]  L. Young,et al.  Epstein-Barr Virus-Encoded Latent Membrane Protein 1 Activates the JNK Pathway through Its Extreme C Terminus via a Mechanism Involving TRADD and TRAF2 , 1999, Journal of Virology.

[11]  B. Williams,et al.  Cell cycle regulation of the double stranded RNA activated protein kinase, PKR , 1999, Oncogene.

[12]  L. Young,et al.  Functional Differences between BHRF1, the Epstein-Barr Virus-Encoded Bcl-2 Homologue, and Bcl-2 in Human Epithelial Cells , 1998, Journal of Virology.

[13]  K. Takada,et al.  Epstein-Barr Virus Contributes to the Malignant Phenotype and to Apoptosis Resistance in Burkitt’s Lymphoma Cell Line Akata , 1998, Journal of Virology.

[14]  S. Anderson,et al.  Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. , 1998, Immunity.

[15]  D. Thorley-Lawson,et al.  EBV persistence in memory B cells in vivo. , 1998, Immunity.

[16]  P. Farrell.  Signal transduction from the Epstein-Barr virus LMP-1 transforming protein. , 1998, Trends in microbiology.

[17]  W. Miller,et al.  The NPC derived C15 LMP1 protein confers enhanced activation of NF-κB and induction of the EGFR in epithelial cells , 1998, Oncogene.

[18]  P. Farrell,et al.  Multiple Functions within the Epstein-Barr Virus EBNA-3A Protein , 1998, Journal of Virology.

[19]  L. Palmqvist,et al.  An ATF/CRE Element Mediates both EBNA2-Dependent and EBNA2-Independent Activation of the Epstein-Barr Virus LMP1 Gene Promoter , 1998, Journal of Virology.

[20]  W. Kolch,et al.  Epstein–Barr virus latent membrane protein‐1 triggers AP‐1 activity via the c‐Jun N‐terminal kinase cascade , 1997, The EMBO journal.

[21]  M. Ueffing,et al.  Latent membrane protein 1 of Epstein–Barr virus mimics a constitutively active receptor molecule , 1997, The EMBO journal.

[22]  M. Rowe,et al.  Epstein-Barr virus latent membrane protein-1 (LMP1) C-terminus activation region 2 (CTAR2) maps to the far C-terminus and requires oligomerisation for NF-κB activation , 1997, Oncogene.

[23]  M. Jäättelä,et al.  The ability of BHRF1 to inhibit apoptosis is dependent on stimulus and cell type , 1997, Journal of virology.

[24]  A. Rickinson,et al.  Epstein-Barr virus leader protein enhances EBNA-2-mediated transactivation of latent membrane protein 1 expression: a role for the W1W2 repeat domain , 1997, Journal of virology.

[25]  E. Kieff,et al.  Epstein-Barr virus nuclear protein LP stimulates EBNA-2 acidic domain-mediated transcriptional activation , 1997, Journal of virology.

[26]  R. Longnecker,et al.  The immunoreceptor tyrosine-based activation motif of Epstein-Barr virus LMP2A is essential for blocking BCR-mediated signal transduction. , 1997, Virology.

[27]  D. Thorley-Lawson,et al.  Identification of the site of Epstein-Barr virus persistence in vivo as a resting B cell , 1997 .

[28]  T. Crook,et al.  Epstein-Barr virus nuclear antigen (EBNA)3C is an immortalizing oncoprotein with similar properties to adenovirus E1A and papillomavirus E7. , 1996, Oncogene.

[29]  W. Lee,et al.  ENHANCED MALIGNANT PROGRESSION OF NASOPHARYNGEAL CARCINOMA CELLS MEDIATED BY THE EXPRESSION OF EPSTEIN–BARR NUCLEAR ANTIGEN 1 IN VIVO , 1996, The Journal of pathology.

[30]  M. Kadin,et al.  Pathophysiology of Hodgkin's disease: functional and molecular aspects. , 1996, Bailliere's clinical haematology.

[31]  S. Goff,et al.  Epstein-Barr virus nuclear protein 2 (EBNA2) binds to a component of the human SNF-SWI complex, hSNF5/Ini1 , 1996, Journal of virology.

[32]  P. Farrell,et al.  Are particular Epstein-Barr virus strains linked to disease? , 1996, Seminars in cancer biology.

[33]  S. Leung,et al.  Hypermethylation of the p16 gene in nasopharyngeal carcinoma. , 1996, Cancer research.

[34]  E. Flemington,et al.  The Epstein‐Barr virus bZIP transcription factor Zta causes G0/G1 cell cycle arrest through induction of cyclin‐dependent kinase inhibitors. , 1996, The EMBO journal.

[35]  A. Levine,et al.  Expression of Epstein‐Barr virus nuclear antigen‐1 induces B cell neoplasia in transgenic mice. , 1996, The EMBO journal.

[36]  Kathryn Flynn,et al.  Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. , 1995, The New England journal of medicine.

[37]  D. Huang,et al.  p16 gene alterations in nasopharyngeal carcinoma. , 1995, Cancer research.

[38]  R. D. Little,et al.  Initiation of latent DNA replication in the Epstein-Barr virus genome can occur at sites other than the genetically defined origin , 1995, Molecular and cellular biology.

[39]  B. Sugden,et al.  An EBNA-1-dependent enhancer acts from a distance of 10 kilobase pairs to increase expression of the Epstein-Barr virus LMP gene , 1995, Journal of virology.

[40]  P. Farrell.  Epstein-Barr virus immortalizing genes. , 1995, Trends in microbiology.

[41]  F. Moreau-Gachelin,et al.  The Spi‐1/PU.1 and Spi‐B ets family transcription factors and the recombination signal binding protein RBP‐J kappa interact with an Epstein‐Barr virus nuclear antigen 2 responsive cis‐element. , 1994, The EMBO journal.

[42]  L. Young,et al.  Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state , 1994, Journal of virology.

[43]  K. Takada,et al.  Isolation of Epstein-Barr virus (EBV)-negative cell clones from the EBV-positive Burkitt's lymphoma (BL) line Akata: malignant phenotypes of BL cells are dependent on EBV , 1994, Journal of virology.

[44]  P. Ling,et al.  Mediation of Epstein-Barr virus EBNA2 transactivation by recombination signal-binding protein J kappa. , 1994, Science.

[45]  G. Peters,et al.  EBNA‐2 and EBNA‐LP cooperate to cause G0 to G1 transition during immortalization of resting human B lymphocytes by Epstein‐Barr virus. , 1994, The EMBO journal.

[46]  P. Farrell,et al.  Epstein-Barr virus nuclear antigen EBNA3C/6 expression maintains the level of latent membrane protein 1 in G1-arrested cells , 1994, Journal of virology.

[47]  C. Dang,et al.  Binding and suppression of the Myc transcriptional activation domain by p107. , 1994, Science.

[48]  M. Rowe,et al.  Epstein-Barr virus-coded BHRF1 protein, a viral homologue of Bcl-2, protects human B cells from programmed cell death. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[49]  L. Young,et al.  Transcripts from the Epstein-Barr virus BamHI A fragment are detectable in all three forms of virus latency , 1993, Journal of virology.

[50]  Carol D. Laherty,et al.  The Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor kappa B. , 1992, The Journal of biological chemistry.

[51]  S. T. Liu,et al.  Cloning and characterization of the latent membrane protein (LMP) of a specific Epstein-Barr virus variant derived from the nasopharyngeal carcinoma in the Taiwanese population. , 1992, Oncogene.

[52]  E. Kieff,et al.  Epstein-Barr virus-encoded small RNAs (EBERs) do not modulate interferon effects in infected lymphocytes , 1992, Journal of virology.

[53]  D. Rowe,et al.  Epstein-Barr virus latent gene expression in uncultured peripheral blood lymphocytes , 1992, Journal of virology.

[54]  U. Prasad,et al.  Expression of Epstein-Barr virus genes and of lymphocyte activation molecules in undifferentiated nasopharyngeal carcinomas. , 1992, The American journal of pathology.

[55]  L. Young,et al.  Three transcriptionally distinct forms of Epstein-Barr virus latency in somatic cell hybrids: cell phenotype dependence of virus promoter usage. , 1992, Virology.

[56]  F. Alexander,et al.  Detection of Epstein-Barr virus genomes in Hodgkin's disease: relation to age. , 1991, Journal of clinical pathology.

[57]  P. Levine,et al.  Patterns of chromosomal breakpoint locations in Burkitt's lymphoma: relevance to geography and Epstein-Barr virus association. , 1991, Blood.

[58]  H. Stein,et al.  Demonstration of monoclonal EBV genomes in Hodgkin's disease and Ki-1-positive anaplastic large cell lymphoma by combined Southern blot and in situ hybridization. , 1989, Blood.

[59]  V. Baichwal,et al.  Transformation of Balb 3T3 cells by the BNLF-1 gene of Epstein-Barr virus. , 1988, Oncogene.

[60]  E. Kieff,et al.  An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells , 1985, Cell.

[61]  G. Hayward,et al.  Sequence-specific DNA binding of the Epstein-Barr virus nuclear antigen (EBNA-1) to clustered sites in the plasmid maintenance region , 1985, Cell.

[62]  P. Farrell,et al.  Epstein-Barr virus genes and cancer cells. , 1997, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[63]  Y. Tomita,et al.  Epstein‐Barr virus in Hodgkin's disease patients in Japan , 1996 .

[64]  T. Tursz,et al.  Sequence polymorphism in the Epstein-Barr virus latent membrane protein (LMP)-2 gene. , 1995, The Journal of general virology.